TICKERNERD
Menu
ADPTADPTHealthcare · Diagnostics & Research

ADPT Stock Forecast: Adaptive Biotechnologies Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$29
+0.21% on the day

The 8 Wall Street analysts covering Adaptive Biotechnologies Corp. hold a median 12-month price target of $25 — -12.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 19 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$4.6B
Ticker Nerd rank
78 / 100
Median analyst target
$25
Analysts covering
8
Revenue$71.6M+21.5% y/y
Operating income−$15.8M
Net income−$39.9M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+18.2%
1M
+16.5%
YTD
+76.2%
1Y
+107.8%
From 52W high
0.0%
From 52W low
+130.5%
$12
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adaptive Biotechnologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Growth
83
Revisions
78
Quality
76
Volatility
70
Accruals
61
Value
55
Size
24
Issuance
14

Momentum (98): The shares have been drifting up relative to others.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26ADPTHigh $28Median $25Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $21Median $25High $28

The green dot is the last close — the median target sits −12.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Piper SandlerMaintainsOverweight$20 → $28
30 July 2026BTIGMaintainsBuy$24 → $25
30 July 2026GuggenheimMaintainsBuy$22 → $25
30 July 2026Morgan StanleyMaintainsEqual-Weight$20 → $22
30 July 2026TD CowenMaintainsBuy$25 → $28
9 July 2026Morgan StanleyMaintainsEqual-Weight$18 → $20
9 July 2026Morgan StanleyMaintainsEqual-Weight—
29 June 2026GuggenheimMaintainsBuy—
17 June 2026BTIGReiteratesBuy—
12 May 2026Morgan StanleyMaintainsEqual-Weight—
6 May 2026BTIGReiteratesBuy—
6 May 2026GuggenheimReiteratesBuy—
6 May 2026JP MorganMaintainsOverweight—
6 May 2026TD CowenMaintainsBuy—
6 Feb 2026BTIGMaintainsBuy—
6 Feb 2026JP MorganMaintainsOverweight—
26 Jan 2026GuggenheimMaintainsBuy—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
6 Nov 2025BTIGMaintainsBuy—
6 Nov 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ADPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Adaptive Biotechnologies Corp. returned +107.8% against +16.3% for the S&P 500, dividends included.

ADPT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26ADPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
7
Fundamentals

Adaptive Biotechnologies Corp. (ADPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−73.4×

Cheaper than 99% of US stocks

Price / sales
14.8×

Cheaper than 11% of US stocks

Price / book
31.9×

Cheaper than 3% of US stocks

EV / EBITDA
−217.6×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
21.5%

Higher than 71% of US stocks

Earnings growth (YoY)
—
Gross margin
71.8%

Higher than 84% of US stocks

Operating margin
−22.0%

Higher than 21% of US stocks

Net margin
−20.7%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−38.8%

Higher than 24% of US stocks

Return on assets
−4.1%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adaptive Biotechnologies Corp. (ADPT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adaptive Biotechnologies Corp. has a market value of $4.6B and an enterprise value of $4.6B.

  • Revenue in the twelve months to 30 June 2026: $308.1M. The latest quarter grew 21.5% year on year.

  • Net income over the same four quarters: −$64.0M, a −20.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.41.

  • Free cash flow in the twelve months to 30 June 2026: −$24.0M.

  • Shares outstanding: 159.1M.

  • Trailing P/E: −73.4×; forward P/E: −154.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Adaptive Biotechnologies Corp. employs 624 people — $494K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

ADPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ADPTAdaptive Biotechnologies Corp.$4.6B
78
BLLNBillionToOne, Inc.$5.0B
15
SHCSotera Health Co.$5.3B
96
GRALGRAIL, Inc.$3.6B
36
RDNTRadNet, Inc.$5.9B
36
VCYTVeracyte, Inc.$3.2B
95
WGSGeneDx Holdings Corp.$2.9B
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adaptive Biotechnologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADPT news & analysis

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

GlobeNewsWire · 17 Sept 2026positive

Adaptive Biotechnologies highlighted updates to the NCCN Guidelines for Multiple Myeloma that establish a dedicated framework for routine MRD assessment and specifically reference clonoSEQ as an FDA-cleared assay, with 10^-6 sensitivity now preferred across the patient journey.

Why it matters — ADPT watchers would care because the updated guidelines strengthen and specifically reference the company's clonoSEQ assay for MRD testing, potentially reinforcing its role in myeloma care.

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Adaptive Biotechnologies Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The item reports on the company's participation in the industry conference.

Why it matters — ADPT watchers would care because a transcript of management's conference presentation can offer insight into the company's current business outlook and strategy directly from its leadership.

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The commercial-stage biotechnology company focuses on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment.

Why it matters — Participation at a major healthcare investment conference gives Adaptive Biotechnologies a platform to present its business to investors and analysts, which ADPT watchers will follow for potential updates on the company's clinical and commercial progress.

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

GeekWire · 18 Aug 2026neutral

Harlan Robins, co-founder and former chief scientific officer of Adaptive Biotechnologies, has raised $15 million for a new startup focused on rethinking how artificial intelligence trains on scientific data. The new venture draws on his experience building large datasets at Adaptive.

Why it matters — A former ADPT co-founder and CSO launching a new AI-focused startup signals where scientific/AI talent and ideas from Adaptive's orbit may flow, giving ADPT watchers insight into emerging competitive or collaborative developments in the space.

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Seeking Alpha · 31 July 2026positive

Adaptive Biotechnologies is transitioning to a pure-play MRD diagnostics company through the planned spin-off of its Immune Medicine division. The company reported 49% year-over-year MRD revenue growth, sequencing gross margins above 70%, and a 14% adjusted EBITDA margin, while refinancing eliminated a 5% perpetual revenue burden.

Why it matters — For ADPT watchers, the shift to a pure-play MRD diagnostics company, combined with strong revenue growth and margin improvements, signals a potential inflection in the company's earnings profile and operational clarity.

FAQ

Frequently asked questions about ADPT stock

What is the ADPT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Adaptive Biotechnologies Corp. have a median 12-month price target of $25, with estimates ranging from $21 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADPT stock a buy right now?

Of the 8 analysts covering Adaptive Biotechnologies Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adaptive Biotechnologies Corp. 78 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADPT?

As at 19 Sept 2026, Adaptive Biotechnologies Corp. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will ADPT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies -12.6% from the last close, and Ticker Nerd's factor model ranks Adaptive Biotechnologies Corp. 78 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADPT stock forecast for 2030?

No analyst covering Adaptive Biotechnologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $28 over the next 12 months.

How has ADPT stock performed over the past year?

Adaptive Biotechnologies Corp. returned +107.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adaptive Biotechnologies Corp. do?

Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery.

What is the latest news on ADPT?

The most recent item we track (GlobeNewsWire, 17 Sept 2026): "Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®". Adaptive Biotechnologies highlighted updates to the NCCN Guidelines for Multiple Myeloma that establish a dedicated framework for routine MRD assessment and specifically reference clonoSEQ as an FDA-cleared assay, with 10^-6 sensitivity now preferred across the patient journey.

Company

About Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery. Its portfolio includes clonoSEQ, a test used to detect and monitor minimal residual disease in cancer patients, along with immunoSEQ-based offerings for immune profiling and research applications. Adaptive Biotechnologies serves healthcare providers, pharmaceutical partners, researchers, and biotech collaborators across oncology and broader immunology-related markets. Headquartered in Seattle, Washington, the company plays a specialized role in translating immune system data into tools for disease detection and treatment support.

CEO Mr. Chad M. Robins M.B.A. · 624 employees · United States · https://www.adaptivebiotech.com